Improve Drug Solubility Research Articles

In Vitro Release Test of Nano-drug Delivery Systems Based on Analytical and Technological Perspectives

Background:Nanotech products are gaining more attention depending on their advantages for improving drug solubility, maintenance of drug targeting, and attenuation of drug toxicity. In vitro release test is the critical physical parameter to determine the pharmaceutical quality of the product, to monitor formulation design and batch-to-batch variation.Methods:Spectrophotometric and chromatographic methods are mostly used in quantification studies from in vitro release test of nano-drug delivery systems. These techniques have advantages and disadvantages with respect to each other considering dynamic range, selectivity, automation, compatibility with in vitro release media and cost per sample.Results:It is very important to determine the correct kinetic profile of active pharmaceutical substances. At this point, the analytical method used for in vitro release tests has become a very critical parameter to correctly assess the profiles. In this review, we provided an overview of analytical methods applied to the in vitro release assay of various nanopharmaceuticals.Conclusion:This review presents practical direction on analytical method selection for in vitro release test on nanopharmaceuticals. Moreover, precautions on analytical method selection, optimization and validation were discussed.

Preparation and evaluation of etoposide-loaded lipid-based nanosuspensions for high-dose treatment of lymphoma.

Aim: High-dose administration of etoposide (VP16) was limited by its poor aqueous solubility and severe systemic toxicity on lymphoma therapy. Herein, a novel VP16-loaded lipid-based nanosuspensions (VP16-LNS) was developed for improving drug solubility, enhancing antitumor effect and reducing systemic toxicity. Materials & methods: VP16-LNS with soya lecithin and D-α-tocopheryl PEG 1000 succinate (TPGS) as stabilizers were prepared by nanoprecipitation method. Results: VP16-LNS exhibited uniform spherical morphology, small particle size and favorable colloidal stability. The concentration of VP16 in VP16-LNS was high enough (1017.67μg/ml) for high-dose therapy on lymphoma. Moreover, VP16-LNS displayed long blood circulation time, selective intratumoral accumulation, remarkable antitumor effect and upregulated safety. Conclusion: VP16-LNS would be an efficient nanoformulation for clinical intravenous application against lymphoma.

Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs

ABSTRACTIntroduction: Solid matrix mediated lipid nanoparticle formulations (LNFs) retain some of the best features of ideal drug carriers necessary for improving the oral absorption and bioavailability (BA) of both hydrophilic and hydrophobic drugs. LNFs with solid matrices may be typically categorized into three major types of formulations, viz., solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and lipid–drug conjugate nanoparticles (LDC-NPs). Solid matrix based LNFs are, potentially, the most appropriate delivery systems for poorly water soluble drugs in need of improved drug solubility, permeability, absorption, or increased oral BA. In addition, LNFs as matrices are able to encapsulate both hydrophobic and hydrophilic drugs in a single matrix based on their excellent ability to form cores and shells. Interestingly, LNFs also act as delivery devices to impart chemical stability to various orally administered drugs.Areas covered: Aim of the review is to forecast the presentation of pharmacokinetic characteristics of solid lipid matrix based nanocarriers which are typically biocompatible, biodegradable and non-toxic carrier systems for efficient oral delivery of various drugs. Efficient delivery is broadly mediated by the fact that lipophilic drugs are readily soluble in lipidic substrates that are capable of permeating across the gut epithelium following oral administration, subsequently delivering the moiety of interest more efficiently across the gut mucosal membrane. This enhances the overall BA of many drugs facing oral delivery challenges by improving their pharmacokinetic profile. This article specifically focuses on the biopharmaceutical and pharmacokinetic aspects of such solid lipid matrix based nanoformulations and possible mechanisms for better drug absorption and improved BA following oral administration. It also briefly reviews methods to access the efficacy of LNFs for improving oral BA of drugs, regulatory aspects and some interesting lipid-derived commercial formulations, with a concluding remark.Expert opinion: LNFs enhance the overall BA of many drugs facing oral delivery challenges by improving their pharmacokinetic profile.

Multicomponent solid dispersion as a formulation strategy to improve drug permeation: A case study on the anti-colorectal cancer irinotecan

Multicomponent solid dispersions (MSD)s are frequently proposed as efficient drug delivery systems to improve drug solubility and bioavailability. In this study, the effects of specific excipients, such as mannitol, inulin, poly(methyl methacrylate-co-methacrylic)acid (PMMA) and cellulose acetate phthalate (CAP) have been tested to potentially improve irinotecan (IRN) permeation in the intestinal tract with the intention to protect the drug from the gastric environment. MSDs were formulated as microparticles by Spray-Drying technique. Raw materials and microparticles have been characterized by FTIR analysis to determine hydrogen bonding. SEM images were recorded to investigate morphology and particle size of drug-loaded microparticles, and thermal analysis was used to confirm that drug physical morphology was maintained during formulation. Finally, in vitro dissolution studies and ex-vivo experiments across colon sections were carried out. The drug-loaded microparticles resulted to have an average particle size of below 6 μm and increased both drug dissolution rate and permeation through the intestine. The use of specific excipients improved properties such as drug dissolution performances and drug absorption through the intestinal barrier. The selected method and excipients increased IRN dissolution rate in all the formulations prepared. Finally, ex-vivo experiments across colon sections demonstrated an increase of drug permeation through MSDs respect pure IRN.

Revaprazan-loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation

The purpose of this research was to develop a novel revaprazan-loaded surface-modified solid dispersion (SMSD) with improved drug solubility and oral bioavailability. The impact of carriers on aqueous solubility of revaprazan was investigated. HPMC and Cremophor A25 were selected as an appropriate polymer and surfactant, respectively, due to their high drug solubility. Numerous SMSDs were prepared with various concentrations of carriers, using distilled water, and the drug solubility of each was assessed. Moreover, the physicochemical properties, dissolution and pharmacokinetics of selected SMSD in rats were assessed in comparison to revaprazan powder. Of the SMSDs assessed, the SMSD composed of revaprazan/HPMC/Cremophor A25 at the weight ratio of 1:0.28:1.12 had the most enhanced drug solubility (∼6000-fold). It was characterized by particles with a relatively rough surface, suggesting that the carriers were attached onto the surface of the unchanged crystalline revaprazan powder. It had a significantly higher dissolution rate, AUC and Cmax, and a faster Tmax value in comparison to revaprazan powder, with a 5.3-fold improvement in oral bioavailability of revaprazan. Therefore, from an environmental perspective, this SMSD system prepared with water, and without organic solvents, should be recommended as a revaprazan-loaded oral pharmaceutical alternative.

A New Approach for Improving the Antibacterial and Tumor Cytotoxic Activities of Pipemidic Acid by Including It in Trimethyl-β-cyclodextrin.

Pipemidic acid (HPPA) is a quinolone antibacterial agent used mostly to treat gram-negative infections of the urinary tract, but its therapeutic use is limited because of its low solubility. Thus, to improve drug solubility, natural cyclodextrins (CDs) are used for their ability of including guest molecules within their cavities. The aim of this work was to evaluate the antibacterial activity and the preliminary anticancer activity of HPPA included into Heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB) as a possible approach for a new innovative formulation. The inclusion complex of HPPA with TRIMEB was prepared in solid state by the kneading method and confirmed by FT-IR and powered X-ray diffraction. The association in aqueous solutions of pipemidic acid with TRIMEB was investigated by UV-Vis spectroscopy. Job’s plots have been drawn by UV-visible spectroscopy to confirm the 1:1 stoichiometry of the host–guest assembly. The antibacterial activity of HPPA, TRIMEB and of their complex was tested on Escherichia coli, Pseudomonas aeruginosa, and Staphilococcus aureus. The complex was able to increase 47.36% of the median antibacterial activity of the free HPPA against E. coli (IC50 = 249 µM vs. 473 µM). Furthermore, these samples were tested on HepG-2 and MCF-7. After 72 h, the median tumoral cytotoxicity exerted by the complex was increased by 78.08% and 94.27% for HepG-2 and MCF-7 respectively, showing a stronger bioactivity of the complex than the single HAPPA.

Comprehensive review of ophthalmic drug delivery systems for effective antibiotic therapy

Background: Ophthalmic drug delivery presents a unique challenge due to the complexity of ocular anatomy and the barriers to drug absorption. Current ocular formulations struggle with issues such as low bioavailability and rapid drug elimination, necessitating advancements in drug delivery systems to enhance therapeutic efficacy. Aim: This review aims to evaluate various ophthalmic drug delivery systems specifically for antibiotic therapies, addressing their efficacy in overcoming ocular barriers and improving drug retention. Methods: A comprehensive literature review was conducted, focusing on different ophthalmic drug delivery systems including topical formulations (eye drops, ointments, hydrogels, and contact lenses), novel systems (in situ gels, nanoparticles, and emulsions), and advanced techniques like intraocular injections. Key developments and challenges associated with each method were analyzed to assess their impact on drug bioavailability and therapeutic outcomes. Results: Traditional ophthalmic delivery methods, such as eye drops and ointments, are limited by factors such as rapid drug clearance and poor bioavailability. Innovations such as in situ gelling systems, nanoparticles, and emulsions have shown promise in extending drug residence time and enhancing bioavailability. Specifically, nanoparticles offer targeted delivery and prolonged action, while hydrogels and emulsions improve drug solubility and stability.

ENHANCE SOLUBILITY AND PROLONG RELEASE OF PROCHLORPERAZINE MALEATE USING FLOATING NANOEMULSION IN SITU GEL

Objective: The objective of this study was to prepare floating gastric in situ gel of prochlorperazine maleate (PM) using nanoemulsion technology to improve drug solubility, bioavailability, reduce dosing frequency, and patient compliance.Methods: Eight nanoemulsion formulas (F1–F8) of PM were prepared by ultrasonication method using oil, surfactants: cosurfactants (Smix) with different types, concentrations, and ratios, and deionized distilled water. The nanoemulsion formulas were characterized to select the optimum recipe from which six floating in situ gel formulas (floating nanoemulsion in situ [FNI] 1-FNI 6) were prepared using sodium alginate as gelling agent, hydroxypropyl methylcellulose (HPMCK) 4M as rate retarding polymer, calcium chloride as cross-linking agent, calcium carbonate as floating agent, and sodium citrate as buffering and neutralizing gastric acid. All FNI formulas were subjected for the evaluation to assess the formulations suitability concerning the dosage form and intended therapeutic purpose.Results: Formulation variables such as the concentration of sodium alginate, HPMCK 4M, calcium carbonate, and calcium chloride affected the gelling properties, formulation viscosity, floating behavior, and in vitro drug release. Formulation FNI 6 showed acceptable floating lag time (55±2.3 s) and >12 h floating duration time, and observe prolong release of the drug in in-situ gelling preparation.Conclusion: The prepared FNI formulas of PM could float in the gastric conditions and released the drug in a sustained manner. The present formulation was enhanced drug solubility with good retention properties and better patient compliance.

ENHANCE SOLUBILITY AND PROLONG RELEASE OF PROCHLORPERAZINE MALEATE USING FLOATING NANOEMULSION IN SITU GEL

Objective: The objective of this study was to prepare floating gastric in situ gel of prochlorperazine maleate (PM) using nanoemulsion technology to improve drug solubility, bioavailability, reduce dosing frequency, and patient compliance.Methods: Eight nanoemulsion formulas (F1–F8) of PM were prepared by ultrasonication method using oil, surfactants: cosurfactants (Smix) with different types, concentrations, and ratios, and deionized distilled water. The nanoemulsion formulas were characterized to select the optimum recipe from which six floating in situ gel formulas (floating nanoemulsion in situ [FNI] 1-FNI 6) were prepared using sodium alginate as gelling agent, hydroxypropyl methylcellulose (HPMCK) 4M as rate retarding polymer, calcium chloride as cross-linking agent, calcium carbonate as floating agent, and sodium citrate as buffering and neutralizing gastric acid. All FNI formulas were subjected for the evaluation to assess the formulations suitability concerning the dosage form and intended therapeutic purpose.Results: Formulation variables such as the concentration of sodium alginate, HPMCK 4M, calcium carbonate, and calcium chloride affected the gelling properties, formulation viscosity, floating behavior, and in vitro drug release. Formulation FNI 6 showed acceptable floating lag time (55±2.3 s) and >12 h floating duration time, and observe prolong release of the drug in in-situ gelling preparation.Conclusion: The prepared FNI formulas of PM could float in the gastric conditions and released the drug in a sustained manner. The present formulation was enhanced drug solubility with good retention properties and better patient compliance.

Challenges of Micro-Emulsion as a Novel Carrier for Drug Delivery

Microemulsions are one of the best candidates for drug delivery because of their long shelf life, improved drug solubilization with ease of preparation and administration. It has unique properties, including clarity, thermodynamically stable and optically isotropic liquid solutions of oil, water and amphiphile. Microemulsions are isotropic, thermodynamically stable transparent (or translucent) systems of oil, water and surfactant, frequently in combination with a cosurfactant with a droplet size usually in the range of 20–200 nm. Microemulsions have great range of applications and uses such as in pharmaceuticals, agrochemicals, cutting oils, biotechnology, food, cosmetics, analytical applications, environmental detoxification etc. The main objective of this review paper is to discuss microemulsions as drug carrier system with other possible applications.

Chitosan-based nanomicelle as a novel platform for targeted delivery of methotrexate

Conventional chemotherapy suffers lack of bioavailability, selectivity and multidrug resistance (MDR). Nano-sized drug delivery systems (DDS) is developing aimed to solve several limitations of conventional drug delivery systems. These systems have been offered for targeting tumor tissue due to their long circulation time and improved drug solubility, retention (EPR) effect, and enhanced permeability. So, the aim of this research was the development and design of a novel targeted nanocarrier for cancer chemotherapy. For this reason, chitosan (CS) was first modified with a chain transfer agent (CTA) to create CS-CTA macroinitiator. Then, the controlled grafting polymerization of itaconic acid (IA) and dimethylaminoethyl methacrylate quaternary ammonium alkyl halide (DMAEMAQ) monomers were occurred using reversible addition–fragmentation chain transfer (RAFT) polymerization to generate CS-g-(PIA-co-PDMAEMAQ) nanomicelles. To follow the cancer cells, fluorescein dye was entrapped into the core of nanomicelles and methotrexate (MTX) anticancer drug as a target ligand was incorporated into the cationic segment of nanomicelles. The chemical structures, biocompatibility, MTX loading capacity, in-vitro cytotoxicity effects and drug targeting ability of the developed nanomicelles were also investigated. Finally, it is expected that the nanomicelles can be used as a novel platform for targeted delivery.

Polymer-drug conjugate therapeutics: advances, insights and prospects.

Polymer-drug conjugates have long been a mainstay of the drug delivery field, with several conjugates successfully translated into clinical practice. The conjugation of therapeutic agents to polymeric carriers, such as polyethylene glycol, offers several advantages, including improved drug solubilization, prolonged circulation, reduced immunogenicity, controlled release and enhanced safety. In this Review, we discuss the rational design, physicochemical characteristics and recent advances in the development of different classes of polymer-drug conjugates, including polymer-protein and polymer-small-molecule drug conjugates, dendrimers, polymer nanoparticles and multifunctional systems. Current obstacles hampering the clinical translation of polymer-drug conjugate therapeutics and future prospects are also presented.

Biomedical Nanomaterials: A Short Insight of Applications

Nanotechnology is rapidly expanding area in the field of science that helps us to manipulate matter at the atomic and molecular level thus having varied and new properties with huge potential. It is the study of extremely small particles ranging from 1-1000 nm. This small size imparts the nanoscale devices their applications in medicine and physiology while permitting them to interact with cells and tissues at subcellular level, with bioreceptors on both the surface and inside of cell membrane thus providing a high degree of functional specificity to the systems. Nanodevices in medicine involves applications of nanoparticles, polymeric micelles, dendrimers, nanotubes, inorganic nanoparticles, nanocrystals and quantam dots which are currently under development as well as constitute the major part of longer range research. Improvement in drug solubility, high drug loading capacity, ease of surface modification, increase in blood circulation time, controlled release and highly site-specific targeted delivery are the advantages responsible for such wide applications of these nanomaterials. The applications include drug and gene delivery to specific site, delivery and detection of specific proteins, biological imaging and biosensors, DNA probing, tissue engineering, pathogens and tumor detection. This article has made an attempt to cover the few insights of nanotechnology as an interesting approach and illustrates various nanosystems along with their advantages, applications and well approved commercially available products.
 Keywords: Polymeric micelles, Dendrimers, Nanotubes, Inorganic nanoparticles, Nanocrystals and Quantam dots

Self Nano Emulsifying Formulation of Nateglinide with Improved Drug Solubility and Dissolution

Self Nano Emulsifying Formulation of Nateglinide with Improved Drug Solubility and Dissolution

Addition of Cationic Surfactants to Lipid-Based Formulations of Poorly Water-Soluble Acidic Drugs Alters the Phase Distribution and the Solid-State Form of the Precipitate Upon In Vitro Lipolysis

It has been previously shown that the interaction of some weakly basic drugs with oppositely charged fatty acids during digestion can influence the solid-state form of the drug if it precipitates. The present study hypothesized the opposite effect for weakly acidic drugs. Tolfenamic acid (TA) and an oppositely charged cationic surfactant, didodecyldimethylammonium bromide (DDAB) were combined in a model medium chain lipid formulation. The phase distribution upon in vitro lipolysis was determined using HPLC and the solid-state form of precipitated TA was determined using X-ray diffraction and crossed polarized light microscopy. TA precipitated in a different polymorphic crystalline form to the starting reference material in the absence of DDAB but precipitated in an amorphous form when DDAB was included in the same formulation. The solubility of TA upon dispersion and digestion of the formulation was considerably higher in the presence of DDAB. The findings point to ionic interactions between TA and DDAB as the reason for the improved drug solubility throughout digestion, and precipitation of drug in an amorphous salt form, analogous to what has been observed in the past for some poorly water-soluble weakly basic drugs with anionic co-formers.

Influence of Hydroxypropylmethylcellulose and Sodium Lauryl Sulfate on the Solubility and Dissolution of Sirolimus in Solvent‐evaporated Solid Dispersions

The object of this study was to investigate the influence of hydroxypropylmethylcellulose (HPMC) and sodium lauryl sulfate (SLS) on the solubility, dissolution, and crystallinity of poorly water‐soluble sirolimus in solvent‐evaporated solid dispersions. For the selection of suitable carriers, the influence of carriers on the solubility of sirolimus was identified. Among the carriers tested, HPMC and SLS gave most improved drug solubility, resulting in selecting them as a suitable polymer and surfactant, respectively. Numerous solvent‐evaporated solid dispersions were prepared with various ratios of sirolimus, SLS, and HPMC via the spray‐drying system. Then, their aqueous solubility, dissolution, and crystallinity were evaluated. All generated formulations significantly enhanced the solubility and dissolution of drug when compared with the sirolimus powder. As the amount of HPMC and SLS were increased, the solubility and dissolution in solvent‐evaporated solid dispersions were increased. Moreover, all the solid dispersions represented the amorphous form of drug. Among the solid dispersions evaluated, the solid dispersion consisted of sirolimus, HPMC, and SLS at the weight ratio of 1:5:0.1 had most improved aqueous solubility (350.83 ± 11.92 vs. 0.003 ± 0.001 μg/mL) and dissolution (12.58 ± 1.31 vs. 1.13 ± 0.60%, at 240 min) compared with drug powder, respectively. This solvent‐evaporated solid dispersion appeared as the round‐shape and reduced the particle sizes. Thus, HPMC and SLS considerably affected the solubility and dissolution. Furthermore, this novel solvent‐evaporated solid dispersion would be a potential candidate for oral preparation of sirolimus.

A water-soluble, mucoadhesive quaternary ammonium chitosan-methyl-β-cyclodextrin conjugate forming inclusion complexes with dexamethasone

The ocular bioavailability of lipophilic drugs, such as dexamethasone, depends on both drug water solubility and mucoadhesion/permeation. Cyclodextrins and chitosan are frequently employed to either improve drug solubility or prolong drug contact onto mucosae, respectively. Although the covalent conjugation of cyclodextrin and chitosan brings to mucoadhesive drug complexes, their water solubility is restricted to acidic pHs. This paper describes a straightforward grafting of methyl-β-cyclodextrin (MCD) on quaternary ammonium chitosan (QA-Ch60), mediated by hexamethylene diisocyanate. The resulting product is a water-soluble chitosan derivative, having a 10-atom long spacer between the quaternized chitosan and the cyclodextrin. The derivative is capable of complexing the model drug dexamethasone and stable complexes were also observed for the lyophilized products. Furthermore, the conjugate preserves the mucoadhesive properties typical of quaternized chitosan and its safety as solubilizing excipient for ophthalmic applications was preliminary assessed by in vitro cytotoxicity evaluations. Taken as a whole, the observed features appear promising for future processing of the developed product into 3D solid forms, such as controlled drug delivery systems, films or drug eluting medical devices.

Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation

Encapsulation of poorly water-soluble drugs into mesoporous materials (e.g. silica) has evolved as a favorable strategy to improve drug solubility and bioavailability. Several techniques (e.g. spray drying, solvent evaporation, microwave irradiation) have been utilized for the encapsulation of active pharmaceutical ingredients (APIs) into inorganic porous matrices. In the present work, a novel chalcone (KAZ3) with anticancer properties was successfully synthesized by Claisen-Schmidt condensation. KAZ3 was loaded into mesoporous (SBA-15 and MCM-41) and non-porous (fumed silica, FS) materials via two techniques; electrohydrodynamic atomization (EHDA) and solvent impregnation. The effect of both loading methods on the physicochemical properties of the particles (e.g. size, charge, entrapment efficiency, crystallinity, dissolution and permeability) was investigated. Results indicated that EHDA technique can load the active in a complete amorphous form within the pores of the silica particles. In contrast, reduced crystallinity (~79%) was obtained for the solvent impregnated formulations. EHDA engineered formulations significantly improved drug dissolution up to 30-fold, compared to the crystalline drug. Ex vivo studies showed EHDA formulations to exhibit higher permeability across rat intestine than their solvent impregnated counterparts. Cytocompatibility studies on Caco-2 cells demonstrated moderate toxicity at high concentrations of the anticancer agent. The findings of the present study clearly show the immense potential of EHDA as a loading technique for mesoporous materials to produce poorly water-soluble API carriers of high payload at ambient conditions. Furthermore, the scale up potential in EHDA technologies indicate a viable route to enhance drug encapsulation and dissolution rate of loaded porous inorganic materials.

Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line

Brain tumor has a low prognosis with only 15% survival rate (5 years after diagnosis). Many of the current therapeutics have limited activity due to their inability to cross the blood brain barrier which retards drug accumulation in tumor site and causes drug resistance. Piperine, a phytochemical drug with poor solubility, could be an alternative to current therapeutics after evading its solubility and permeability limitations. Piperine micellization was optimized to improve drug solubility. Positively charged trimethyl-chitosan was synthesized then electrostatically adsorbed onto piperine nanomicelles forming core-shell nanoparticles. Physicochemical and morphological characterizations, and in-vitro release were performed. Cytotoxicity on human brain cancer cell line (Hs683) was evaluated using IC50 determination, cell cycle arrest analysis, apoptosis and enzyme-linked immunosorbent assay. Optimum piperine-loaded core-shell nanoparticles were successfully fabricated with double-phase release model. Significant improvement in cytotoxicity than free drug was noted with increasing in G2/M-phase and pre-GI-phase population, apoptotic/necrotic rates and inhibition of CDK2a.

Effect of β-cyclodextrin and Hydroxypropyl β-cyclodextrin on Aqueous Stability, Solubility and Dissolution of Novel Anti-cancer Drug Rigosertib

Aim: To study Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin on aqueous stability, solubility and dissolution of novel anti-cancer drug Rigosertib. Methods: β-cyclodextrin and hydroxypropyl β-cyclodextrin were used to form complex with Rigosertib. The effect of cyclodextrins on drug solubility was studied using phase solubility method. Physico-chemical characterization of drug cyclodextrin complex was performed using differential scanning calorimeter, X-Ray diffraction, Infrared spectroscopy and Scanning electron microscopy. Dissolution profiles of drug-cyclodextrin complexes showed better drug release compared to untreated drug in pH 1, 2, 4 and 5.5 dissolution medium. Results: Rigosertib exhibits poor solubility and chemical instability in acidic solutions. Poor aqueous stability along with limited solubility in acidic conditions can result in limited oral bioavailability of the drug. Both analogues showed positive effect on drug solubility. Hydroxypropyl β-cyclodextrin performed better compared to β-cyclodextrin to improve drug solubility. In addition, presence of both cyclodextrin analogues improved drug stability in acidic solutions. Physico-chemical characterization of drug cyclodextrin complex was performed using differential scanning calorimeter, X-Ray diffraction, Infrared spectroscopy and Scanning electron microscopy. Dissolution profiles of drug-cyclodextrin complexes showed better drug release compared to untreated drug in pH 1, 2, 4 and 5.5 dissolution medium. Conclusion: Improved drug solubility and chemical stability in acidic conditions can be attributed to complex formation between drug and cyclodextrin.